Enzymatica commissioned the market research company Gfk/IPSOS to compile four previous user surveys from 2015 to 2019 regarding use of ColdZyme. A total of 805 individuals were included in the four surveys on which the report is based, 405 of whom were users of other products in the common cold category and 400 were ColdZyme users. The analysis focused specifically on the experience of the 146 respondents who used ColdZyme preventively, before experiencing any common cold symptoms, as well as outcomes if they did come down with a common cold.
Almost half (48%) of respondents answered that use of ColdZyme before cold symptoms arise, or upon potential exposure to a cold virus, results in fewer episodes of common colds. Among respondents who primarily used ColdZyme preventively, almost 3 of 4 (72%) estimated that their colds were less severe, defined as milder or with fewer days with common cold symptoms. The respondents felt that ColdZyme is most effective against the symptoms sore throat and irritated throat. They experienced fewer side effects with ColdZyme than with other self-care products and drugs used to alleviate, treat or prevent common cold symptoms.
The majority of the users are satisfied with ColdZyme and the repurchase rate is high, since 92% intend to buy ColdZyme again within the next 12 months.
“The report convincingly shows that customers experience that use of ColdZyme leads to fewer and milder colds without increased side effects compared with other self-care products,” says Fredrik Lindberg, CEO of Enzymatica.
For more information, please contact:
Fredrik Lindberg, CEO Enzymatica AB
Phone: +46 (0)708-86 53 70 | Email: email@example.com
Carl-Johan Wachtmeister, Communication manager Enzymatica AB
Phone: +46 (0)701-88 50 21 | Email: firstname.lastname@example.org
About Enzymatica AB
Enzymatica AB is a Swedish life science company that develops and sells health care products for primarily conditions of the ear-nose-and-throat region. The products are based on a barrier technology that includes marine enzymes. The company’s first product is the medical device ColdZyme®, a mouth spray against common cold. The product has been launched in about ten markets. The strategy is to continue to grow by developing more health care products and strengthening the company’s position in existing markets and expanding into new geographic markets through established partners. The company has its headquarters in Lund and is listed on Nasdaq First North Growth Market. For more information, visit: www.enzymatica.com and www.enzymatica.se/en/section/media/press-releases
Enzymatica’s certified adviser is Erik Penser Bank. Phone: +46 (0)8 463 83 00. Email: email@example.com